Tiotropium bromide for cystic fibrosis

Bibliography

• MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014;161(4):233-41
   PubMed Web of Science ®Google Scholar
• Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 2011;183(11):1463-71
   PubMed Web of Science ®Google Scholar
• Konstan MW, VanDevanter DR, Rasouliyan L, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010;45(12):1167-72
   PubMed Web of Science ®Google Scholar
• Mogayzel PJJr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
   PubMed Web of Science ®Google Scholar
• Halfhide C, Evans HJ, Couriel J. Inhaled bronchodilators for cystic fibrosis. Cochrane Database Syst Rev 2005(4):CD003428
   Google Scholar
• Colombo JL. Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 2003;9(6):504-8
   PubMed Web of Science ®Google Scholar
• Weintraub SJ, Eschenbacher WL. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF. Chest 1989;95(4):861-4
   PubMed Web of Science ®Google Scholar
• Davis PB, Shelhamer JR, Kaliner M. Abnormal adrenergic and cholinergic sensitivity in cystic fibrosis. N Engl J Med 1980;302(26):1453-6
   Google Scholar
• van Haren EH, Lammers JW, Festen J, van Herwaarden CL. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur Respir J 1992;5(9):1083-8
   Google Scholar
• Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 2015;16(1):45-56
   PubMed Web of Science ®Google Scholar
• Adam RJ, Michalski AS, Bauer C, et al. Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med 2013;188(12):1434-41
   Google Scholar
• Hall GL, Logie KM, Parsons F, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. PLoS ONE 2011;6(8):e23932
   PubMed Web of Science ®Google Scholar
• Sly PD, Brennan S, Gangell C, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009;180(2):146-52
   PubMed Web of Science ®Google Scholar
• Balfour-Lynn IM, Elborn JS. "CF asthma": what is it and what do we do about it? Thorax 2002;57(8):742-8
   PubMed Web of Science ®Google Scholar
• Michoud MC, Robert R, Hassan M, et al. Role of the cystic fibrosis transmembrane conductance channel in human airway smooth muscle. Am J Respir Cell Mol Biol 2009;40(2):217-22
   Google Scholar
• McCuaig S, Martin JG. How the airway smooth muscle in cystic fibrosis reacts in proinflammatory conditions: implications for airway hyper-responsiveness and asthma in cystic fibrosis. Lancet Respir Med 2013;1(2):137-47
   PubMed Web of Science ®Google Scholar
• Govindaraju V, Michoud MC, Ferraro P, et al. The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis. Respir Res 2008;9:76
   PubMedGoogle Scholar
• Risse PA, Jo T, Suarez F, et al. Interleukin-13 inhibits proliferation and enhances contractility of human airway smooth muscle cells without change in contractile phenotype. Am J Physiol Lung Cell Mol Physiol 2011;300(6):L958-66
   Google Scholar
• Kudo M, Melton AC, Chen C, et al. IL-17A produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med 2012;18(4):547-54
   PubMed Web of Science ®Google Scholar
• Santus P, Buccellati C, Centanni S, et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol Res 2012;66(4):343-8
   PubMed Web of Science ®Google Scholar
• Regamey N, Ochs M, Hilliard TN, et al. Increased airway smooth muscle mass in children with asthma, cystic fibrosis, and non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2008;177(8):837-43
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today 2011;16(23-24):1084-91
   PubMed Web of Science ®Google Scholar
• Pan J, Luk C, Kent G, et al. Pulmonary neuroendocrine cells, airway innervation, and smooth muscle are altered in Cftr null mice. Am J Respir Cell Mol Biol 2006;35(3):320-6
   PubMed Web of Science ®Google Scholar
• Taouil K, Hinnrasky J, Hologne C, et al. Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway. J Biol Chem 2003;278(19):17320-7
   PubMed Web of Science ®Google Scholar
• Eggleston PA, Rosenstein BJ, Stackhouse CM, et al. A controlled trial of long-term bronchodilator therapy in cystic fibrosis. Chest 1991;99(5):1088-92
   PubMed Web of Science ®Google Scholar
• Konig P, Poehler J, Barbero GJ. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis. Pediatr Pulmonol 1998;25(1):32-6
   PubMed Web of Science ®Google Scholar
• Hordvik NL, Sammut PH, Judy CG, Colombo JL. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Pediatr Pulmonol 2002;34(4):287-96
   PubMed Web of Science ®Google Scholar
• Mortensen J, Hansen A, Falk M, et al. Reduced effect of inhaled beta 2-adrenergic agonists on lung mucociliary clearance in patients with cystic fibrosis. Chest 1993;103(3):805-11
   PubMed Web of Science ®Google Scholar
• Wood RE, Wanner A, Hirsch J, Farrell PM. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline. Am Rev Respir Dis 1975;111(6):733-8
   PubMed Web of Science ®Google Scholar
• Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 2002;33(4):293-306
   PubMed Web of Science ®Google Scholar
• Mortensen J. Bronchoscintigraphy and pulmonary clearance of 99mTc-albumin colloid in the study of mucociliary clearance. Dan Med Bull 1998;45(2):195-209
   Google Scholar
• ZuWallack AR, ZuWallack RL. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. Expert Opin Pharmacother 2004;5(8):1827-35
   PubMed Web of Science ®Google Scholar
• Haddad el B, Rousell J. Regulation of the expression and function of the M2 muscarinic receptor. Trends Pharmacol Sci 1998;19(8):322-7
   Google Scholar
• Restrepo RD. Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance? Respir Care 2007;52(9):1159-73
   Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem 2015;58(10):4131-64
   PubMed Web of Science ®Google Scholar
• Hasani A, Toms N, Agnew JE, et al. The effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPD. Chest 2004;125(5):1726-34
   PubMed Web of Science ®Google Scholar
• Disse B, Speck GA, Rominger KL, et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999;64(6-7):457-64
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-54
   PubMed Web of Science ®Google Scholar
• Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Respir Med 2008;102(1):32-41
   Google Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of Respimat Soft Mist Inhaler. Int J Pharm 2004;283(1-2):1-9
   PubMed Web of Science ®Google Scholar
• Konstan MW, Sharma A, Moroni-Zentgraf P, et al. Safety, tolerability, and plasma exposure of tiotropium respimat((R)) in children and adults with cystic fibrosis. J Aerosol Med Pulm Drug Deliv 2015;28(2):137-44
   Google Scholar
• Bradley JM, Koker P, Deng Q, et al. Testing two different doses of tiotropium Respimat(R) in cystic fibrosis: phase 2 randomized trial results. PLoS ONE 2014;9(9):e106195
   Google Scholar
• Ratjen F, Koker P, Geller DE, et al. Tiotropium Respimat(R) in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials. J Cyst Fibros 2015. [Epub ahead of print]
   Google Scholar
• Sharma A, Geller DE, Moroni-Zentgraf P, et al. Pooled analysis of tiotropium Respimat((R)) pharmacokinetics in cystic fibrosis. Pulm Pharmacol Ther 2014;29(2):217-23
   Google Scholar
• Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38(5):1071-80
   PubMed Web of Science ®Google Scholar
• Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185(6):645-52
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010;363(21):1991-2003
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
   PubMed Web of Science ®Google Scholar
• Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12(4):367-76
   PubMed Web of Science ®Google Scholar